SI1797037T1 - Postopek priprave 4-(4-((((4-kloro-3-(trifluorometil)fenil)amino)karbonil)amino) fenioksi)N-metilpiridin-2-karboksamida - Google Patents

Postopek priprave 4-(4-((((4-kloro-3-(trifluorometil)fenil)amino)karbonil)amino) fenioksi)N-metilpiridin-2-karboksamida

Info

Publication number
SI1797037T1
SI1797037T1 SI200531947T SI200531947T SI1797037T1 SI 1797037 T1 SI1797037 T1 SI 1797037T1 SI 200531947 T SI200531947 T SI 200531947T SI 200531947 T SI200531947 T SI 200531947T SI 1797037 T1 SI1797037 T1 SI 1797037T1
Authority
SI
Slovenia
Prior art keywords
phenylćaminoćcarbonyl
aminoćphenyoxyćn
methylpyridine
carboxamide
trifluoromethyl
Prior art date
Application number
SI200531947T
Other languages
English (en)
Inventor
Michael Logers
Reinhold Gehring
Oliver Kuhn
Mike Matthaus
Klaus Mohrs
Matthias Muller-Gliemann
Jurgen Stiehl
Mathias Berwe
Jana Lenz
Werner Heilmann
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35457568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1797037(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of SI1797037T1 publication Critical patent/SI1797037T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
SI200531947T 2004-09-29 2005-09-20 Postopek priprave 4-(4-((((4-kloro-3-(trifluorometil)fenil)amino)karbonil)amino) fenioksi)N-metilpiridin-2-karboksamida SI1797037T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04023131 2004-09-29
PCT/EP2005/010118 WO2006034796A1 (en) 2004-09-29 2005-09-20 Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide
EP05794785.5A EP1797037B1 (en) 2004-09-29 2005-09-20 Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenyoxy}n-methylpyridine-2-carboxamide

Publications (1)

Publication Number Publication Date
SI1797037T1 true SI1797037T1 (sl) 2015-06-30

Family

ID=35457568

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200531947T SI1797037T1 (sl) 2004-09-29 2005-09-20 Postopek priprave 4-(4-((((4-kloro-3-(trifluorometil)fenil)amino)karbonil)amino) fenioksi)N-metilpiridin-2-karboksamida

Country Status (35)

Country Link
US (1) US8124782B2 (sl)
EP (1) EP1797037B1 (sl)
JP (2) JP2008514657A (sl)
KR (1) KR101263032B1 (sl)
CN (1) CN101052619B (sl)
AR (1) AR053973A1 (sl)
AU (1) AU2005289099B2 (sl)
BR (1) BRPI0515944B1 (sl)
CA (1) CA2581835C (sl)
CU (1) CU23754B7 (sl)
CY (1) CY1116126T1 (sl)
DK (1) DK1797037T3 (sl)
DO (1) DOP2005000183A (sl)
EC (1) ECSP077357A (sl)
ES (1) ES2532377T3 (sl)
GT (1) GT200500269A (sl)
HK (1) HK1113484A1 (sl)
HN (1) HN2005000768A (sl)
HR (1) HRP20150295T1 (sl)
IL (1) IL182046A0 (sl)
MA (1) MA28883B1 (sl)
MY (1) MY149873A (sl)
NO (1) NO339647B1 (sl)
NZ (1) NZ554119A (sl)
PE (5) PE20091586A1 (sl)
PL (1) PL1797037T3 (sl)
PT (1) PT1797037E (sl)
SG (1) SG155997A1 (sl)
SI (1) SI1797037T1 (sl)
SV (1) SV2006002243A (sl)
TW (1) TWI382973B (sl)
UA (1) UA90691C2 (sl)
UY (1) UY29143A1 (sl)
WO (1) WO2006034796A1 (sl)
ZA (1) ZA200702511B (sl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000041698A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
DE602004007382T2 (de) 2003-05-20 2008-04-17 Bayer Pharmaceuticals Corp., West Haven Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
DE602004010407T2 (de) 2003-07-23 2008-10-16 Bayer Pharmaceuticals Corp., West Haven Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
EP1797038B1 (en) 2004-09-29 2012-06-13 Bayer Pharma Aktiengesellschaft Thermodynamically stable form of bay 43-9006 tosylate
UA90691C2 (en) 2004-09-29 2010-05-25 Баер Шеринг Фарма Акциенгезельшафт Process for the preparation of 4-{ 4-[({ [4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide
CA2601955C (en) 2005-03-07 2012-07-10 Bayer Healthcare Ag Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
CA2669158A1 (en) * 2006-11-14 2008-05-22 Bayer Schering Pharma Aktiengesellschaft Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
NZ583790A (en) 2007-09-10 2012-04-27 Cipla Ltd Process for the preparation the raf kinase inhibitor sorafenib and intermediates for use in the process
WO2009054004A2 (en) * 2007-10-22 2009-04-30 Natco Pharma Limited Process for the preparation of sorafenib
EP2231612A1 (en) 2008-01-17 2010-09-29 Sicor, Inc. Polymorph form iii of sorafenib tosylate, sorafenib tosylate methanol solvate and sorafenib tosylate ethanol solvate, and processes for preparation thereof
US20090253913A1 (en) * 2008-03-06 2009-10-08 Pierluigi Rossetto Process for the preparation of sorafenib and salts thereof
CN103254126A (zh) * 2008-09-19 2013-08-21 苏州泽璟生物制药有限公司 氘代的ω-二苯基脲及衍生物以及包含该化合物的药物组合物
WO2011036647A1 (en) 2009-09-24 2011-03-31 Ranbaxy Laboratories Limited Process for the preparation of sorafenib tosylate
WO2011036648A1 (en) 2009-09-24 2011-03-31 Ranbaxy Laboratories Limited Polymorphs of sorafenib acid addition salts
US8552197B2 (en) * 2009-11-12 2013-10-08 Ranbaxy Laboratories Limited Sorafenib ethylsulfonate salt, process for preparation and use
WO2011076711A2 (en) 2009-12-23 2011-06-30 Ratiopharm Gmbh Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methylpyridine-2-carboxamide
AU2011210326B2 (en) 2010-01-29 2014-10-09 Sun Pharmaceutical Industries Limited Sorafenib dimethyl sulphoxide solvate
CN102190616B (zh) * 2010-03-18 2015-07-29 苏州泽璟生物制药有限公司 一种氘代的ω-二苯基脲的合成及生产的方法和工艺
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
CN102617458A (zh) * 2010-05-18 2012-08-01 张南 抗癌用化合物的制备方法
JP2013531067A (ja) 2010-07-19 2013-08-01 バイエル ヘルスケア リミティド ライアビリティ カンパニー 疾病及び状態の処置及び予防のためのフルオロ置換オメガ−カルボキシアリールジフェニル尿素を用いた組み合わせ薬
PE20140165A1 (es) 2010-10-01 2014-02-26 Bayer Ip Gmbh Combinaciones que contienen n-(2-arilamino)arilsulfonamida
WO2012071425A1 (en) 2010-11-22 2012-05-31 Teva Pharmaceutical Industries Ltd. Solid state forms of sorafenib besylate, and processes for preparations thereof
EP2559431A1 (en) 2011-08-17 2013-02-20 Ratiopharm GmbH Pharmaceutical composition comprising 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
CN103664771B (zh) * 2012-09-19 2016-03-30 齐鲁制药有限公司 索拉非尼的晶型a及其制备方法
WO2014118807A1 (en) * 2013-02-04 2014-08-07 Intas Pharmaceuticals Limited A novel process for the preparation of sorafenib tosylate form iii
CN104710354A (zh) * 2013-12-13 2015-06-17 江苏豪森药业股份有限公司 高纯度索拉非尼的制备方法
CN104761492A (zh) * 2014-01-03 2015-07-08 正大天晴药业集团股份有限公司 对甲苯磺酸索拉非尼的晶型及其制备方法
CN104177292A (zh) * 2014-08-08 2014-12-03 亿腾药业（泰州）有限公司 一种工业化生产甲苯磺酸索拉非尼多晶型ⅰ的方法
CN110204483B (zh) * 2014-12-01 2021-06-29 石药集团中奇制药技术（石家庄）有限公司 一种甲苯磺酸索拉非尼新晶型及其制备方法
EP3109236B1 (en) 2015-06-23 2017-08-09 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Scalable process for the preparation of sorafenib tosylate ethanol solvate and sorafenib tosylate form iii
CN105181844A (zh) * 2015-09-11 2015-12-23 江苏嘉逸医药有限公司 一种高效液相色谱法测定甲苯磺酸索拉非尼含量和有关物质的方法
CN105585523A (zh) * 2015-12-29 2016-05-18 上海北卡医药技术有限公司 一种对甲苯磺酸索拉非尼的新晶型及其制备方法和用途
CN107840823B (zh) * 2016-09-20 2021-08-17 意大利合成制造有限公司 用于制备甲苯磺酸索拉非尼乙醇溶剂化物和iii型甲苯磺酸索拉非尼的可变规模的方法
CN107915676A (zh) * 2017-10-26 2018-04-17 魏海霞 索拉非尼的制备方法
CN109796400B (zh) * 2017-11-16 2022-07-29 四川科伦药物研究院有限公司 一种甲苯磺酸索拉菲尼晶型及其制备方法
CN113773249A (zh) * 2020-06-10 2021-12-10 杭州中美华东制药有限公司 索拉非尼游离碱晶型Form X及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU86960A1 (fr) * 1987-07-31 1989-03-08 Oreal Procede de preparation de piperidino-6 diamino-2,4 pyrimidine oxyde-3 et composes nouveaux
JPH02934A (ja) * 1988-05-27 1990-01-05 Konica Corp 非線形光学材料
JP2971291B2 (ja) * 1993-06-02 1999-11-02 田辺製薬株式会社 光学活性２−アミノ酪酸の製法
JP3866323B2 (ja) * 1996-03-27 2007-01-10 ポーラ化成工業株式会社 新規ｎ−ベンジルベンズアミド誘導体
JPH09316069A (ja) * 1996-03-28 1997-12-09 Ajinomoto Co Inc 新規キサントン誘導体
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
TR200102020T2 (tr) * 1999-01-13 2003-01-21 Bayer Corporation Raf kinaz inhibitörleri olarak w-karboksiaril sübstitüe edilmiş difenil üreler.
GB2367816A (en) * 2000-10-09 2002-04-17 Bayer Ag Urea- and thiourea-containing derivatives of beta-amino acids
DE60216139T3 (de) * 2001-12-03 2018-11-15 Bayer Healthcare Llc Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
US20030207872A1 (en) * 2002-01-11 2003-11-06 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
DE10203086A1 (de) * 2002-01-28 2003-07-31 Bayer Ag 5-Ring Heterozyklen
AU2003209116A1 (en) * 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
KR20050087776A (ko) * 2002-08-13 2005-08-31 산도즈 아게 세프디니르 중간체
AU2003301430A1 (en) * 2002-10-21 2004-05-04 Kirin Beer Kabushiki Kaisha N-{2-chloro-4-((6,7-dimethoxy-4-quinolyl)oxy)phenyl}-n'-(5-methyl-3-isoxazolyl)urea salt in crystalline form
DE602004007382T2 (de) * 2003-05-20 2008-04-17 Bayer Pharmaceuticals Corp., West Haven Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
UA90691C2 (en) 2004-09-29 2010-05-25 Баер Шеринг Фарма Акциенгезельшафт Process for the preparation of 4-{ 4-[({ [4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide

Also Published As

Publication number Publication date
PL1797037T3 (pl) 2015-07-31
PE20091585A1 (es) 2009-10-31
PE20091586A1 (es) 2009-10-31
NO339647B1 (no) 2017-01-16
TW200626551A (en) 2006-08-01
CN101052619A (zh) 2007-10-10
BRPI0515944A (pt) 2008-08-12
NZ554119A (en) 2010-07-30
PE20091587A1 (es) 2009-11-05
PE20060825A1 (es) 2006-10-20
HRP20150295T1 (hr) 2015-05-22
HK1113484A1 (en) 2008-10-03
JP2008514657A (ja) 2008-05-08
EP1797037A1 (en) 2007-06-20
BRPI0515944B1 (pt) 2021-11-09
CU23754B7 (es) 2012-01-31
KR20070058676A (ko) 2007-06-08
CY1116126T1 (el) 2017-02-08
KR101263032B1 (ko) 2013-05-09
WO2006034796A1 (en) 2006-04-06
MA28883B1 (fr) 2007-09-03
PE20091584A1 (es) 2009-10-28
IL182046A0 (en) 2007-07-24
SG155997A1 (en) 2009-10-29
CU20070069A7 (es) 2010-11-27
US20080262236A1 (en) 2008-10-23
MY149873A (en) 2013-10-31
HN2005000768A (es) 2010-09-17
CN101052619B (zh) 2012-02-22
ZA200702511B (en) 2008-07-30
NO20072173L (no) 2007-06-14
UA90691C2 (en) 2010-05-25
TWI382973B (zh) 2013-01-21
DK1797037T3 (en) 2015-03-30
DOP2005000183A (es) 2006-03-31
JP5583190B2 (ja) 2014-09-03
CA2581835A1 (en) 2006-04-06
CA2581835C (en) 2012-12-18
SV2006002243A (es) 2006-10-13
AU2005289099B2 (en) 2012-07-19
AU2005289099A1 (en) 2006-04-06
JP2013067625A (ja) 2013-04-18
PT1797037E (pt) 2015-03-17
US8124782B2 (en) 2012-02-28
UY29143A1 (es) 2006-04-28
ECSP077357A (es) 2007-04-26
ES2532377T3 (es) 2015-03-26
EP1797037B1 (en) 2014-12-17
AR053973A1 (es) 2007-05-30
GT200500269A (es) 2006-05-11

Similar Documents

Publication Publication Date Title
SI1797037T1 (sl) Postopek priprave 4-(4-((((4-kloro-3-(trifluorometil)fenil)amino)karbonil)amino) fenioksi)N-metilpiridin-2-karboksamida
TWI340137B (en) Preparation process
IL173456A0 (en) Process for the preparation of 4-amino-3-quinolinecarbonitriles
HK1163672A1 (en) Processes for the preparation of compounds
HK1085480A1 (en) Process for the preparation of roflumilast
TWI367257B (en) Process for the preparation of 2-butanol
PT1748990E (pt) Processo para a preparação de telmisartan
ZA200804264B (en) Process for the preparation of ferri-succinylcasein
IL177561A0 (en) Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols
IL175743A0 (en) Process for the preparation of thiazolopyrimidines
PL1763508T3 (pl) Sposób wytwarzania mocznika
ZA200601910B (en) Process for the preparation of organosilances
GB2436262B (en) Process for the preparation of pantoprazole sodium
IL182421A0 (en) Process for the preparation of pyrazoles
GB0406635D0 (en) Process for the preparation of an emulsion
IL191052A0 (en) Process for the preparation of tamsulosin and related compounds
PL378094A1 (pl) Sposób wytwarzania aldehydów
HK1095145A1 (en) Process for the preparation of n-arylmorpholinones n-
HUP0401379A3 (en) Process for the preparation of risperidon
IL178960A0 (en) Process for the preparation of pyridin-2-ylmethylsulphinyl-1h-benzimidazol compounds
IL177353A0 (en) Process for the preparation of aq4n
HK1128287A1 (en) Process for the preparation of tryptase inhibitors
IL178237A0 (en) Process for the preparation of rosiglitazone
GB0415076D0 (en) Process for the preparation of gabapentin
HK1087111A1 (en) Process for the preparation of nicotinaldehydes